GACM
VIRX

Green Arrow Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Green Arrow Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-714
Closed -$778K – 312
2013
Q2 		$778K Buy
+714
New +$796K 0.06% 211

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Green Arrow Capital Management's VIRX Position: Q3 2013 in Review

Green Arrow Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2013, closing a stake of 714 shares — an estimated $778K sold.

Green Arrow Capital Management first reported a position in VIRX in Q2 2013 and held it in 1 quarter. The position peaked at $778K in Q2 2013. 73 funds tracked by Wall St. Rank hold VIRX as of Q3 2013.

  • Green Arrow Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2013 after selling out during the quarter.
  • Green Arrow Capital Management sold 714 Viracta Therapeutics, Inc. Common Stock shares in Q3 2013, an estimated $778K.
  • Green Arrow Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 1 quarter.
  • Green Arrow Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $778K in Q2 2013.
  • 73 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2013.

Based on Green Arrow Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.